Clinical trial NCT05064059: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Official title: A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Colorectal Cancer
Keywords: Programmed Cell Death-1 (PD1, PD-1),
Programmed Cell Death Receptor Ligand 1 (PDL1, PD-L1)
Programmed Cell Death Receptor Ligand 2 (PDL2, PD-L2)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2021-10-01
Enrollment: 441
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil).

The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.


Eligibility criteria: Inclusion Criteria:

* Has a histologically confirmed colorectal adenocarcinoma that is metastatic and unresectable.
* Has measurable disease per RECIST 1.1 as assessed by the local site investigator.
* Has been previously treated for the disease and radiographically progressed on or after or could not tolerate standard treatment.
* Submits an archival (≤ 5 years) or newly obtained tumor tissue sample or newly obtained tumor tissue sample that has not been previously irradiated.
* Has an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 to 1 within 10 days prior to first dose of study intervention.
* Has a life expectancy of at least 3 months, based on the investigator assessment.
* Has the ability to swallow and retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption.
* Has adequate organ function.

Exclusion Criteria:

* Has previously been found to have deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) tumor status.
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease.
* Has a history of acute or chronic pancreatitis.
* Has neuromuscular disorders associated with an elevated creatine kinase (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
* Has urine protein greater than or equal to 1g/24h.
* A woman of childbearing potential who has a positive urine/serum pregnancy test within 24/72 hours prior to the first dose of study intervention.
* Has received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2), anti-lymphocyte activation gene 3 (LAG-3) antibody, with a tyrosine kinase inhibitor (TKI; eg, lenvatinib) other than rapidly accelerated fibrosarcoma (RAF) inhibitors (binimetinib is permitted if combined with a RAF inhibitor), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4, OX-40, cluster of differentiation \[CD\] 137).
* Has previously received regorafenib or TAS-102.
* Has received prior systemic anticancer therapy including investigational agents within 28 days before randomization.
* Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
* Has an active autoimmune disease that has required systemic treatment in past 2 years.
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* Has an active infection requiring systemic therapy (eg, tuberculosis, known viral or bacterial infections, etc.).
* Has a known history of human immunodeficiency virus (HIV) infection.
* Has known history of Hepatitis B or known active Hepatitis C virus infection.
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
* Has had an allogenic tissue/solid organ transplant.

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: Up to approximately 26 months
Secondary outcomes:
measure: Progression-Free Survival (PFS) according per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR)
timeFrame: Up to approximately 19 months
measure: Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR
timeFrame: Up to approximately 19 months
measure: Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR
timeFrame: Up to approximately 19 months
measure: Number of Participants Who Experience at least One Adverse Event (AE)
timeFrame: Up to approximately 27 months
measure: Number of Participants Who Discontinue Study Treatment Due to an AE
timeFrame: Up to approximately 24 months
measure: Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
timeFrame: Baseline and up to approximately 25 months
measure: Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
timeFrame: Baseline and up to approximately 25 months
measure: Change from Baseline in EORTC QLQ-C30 Appetite Loss (Item 13) Score
timeFrame: Baseline and up to approximately 25 months
measure: Change from Baseline in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
timeFrame: Baseline and up to approximately 25 months
measure: Time to Deterioration (TTD) in EORTC QLQ-C30 GHS (Item 29) and QoL (Item 30) Combined Score
timeFrame: Baseline and up to approximately 25 months
measure: TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
timeFrame: Baseline and up to approximately 25 months
measure: TTD in in EORTC QLQ-C30 Appetite Loss (Item 13) Score
timeFrame: Baseline and up to approximately 25 months
measure: TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
timeFrame: Baseline and up to approximately 25 months
Other outcomes:
Locations:
city: Washington
country: United States
facility: Georgetown University Hospital ( Site 1148)
state: District of Columbia
city: Washington
country: United States
facility: Sibley Memorial Hospital ( Site 1143)
state: District of Columbia
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1118)
state: Georgia
city: Louisville
country: United States
facility: Norton Cancer Institute ( Site 1139)
state: Kentucky
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey ( Site 1105)
state: New Jersey
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center ( Site 1703)
state: New York
city: Portland
country: United States
facility: Oregon Health & Science University ( Site 1141)
state: Oregon
city: Charleston
country: United States
facility: MUSC Hollings Cancer Center ( Site 1715)
state: South Carolina
city: Germantown
country: United States
facility: The West Clinic, PLLC dba West Cancer Center ( Site 1149)
state: Tennessee
city: Dallas
country: United States
facility: UT Southwestern Medical Center ( Site 1709)
state: Texas
city: Murray
country: United States
facility: Intermountain Medical Center ( Site 1707)
state: Utah
city: Fairfax
country: United States
facility: Inova Schar Cancer Institute ( Site 1130)
state: Virginia
city: Richmond
country: United States
facility: VCU Health Adult Outpatient Pavillion ( Site 1712)
state: Virginia
city: Roanoke
country: United States
facility: Blue Ridge Cancer Care ( Site 1718)
state: Virginia
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance ( Site 1107)
state: Washington
city: Westmead
country: Australia
facility: Westmead Hospital ( Site 0057)
state: New South Wales
city: Herston
country: Australia
facility: Royal Brisbane and Women s Hospital ( Site 0058)
state: Queensland
city: Woodville South
country: Australia
facility: Queen Elizabeth Hospital ( Site 0050)
state: South Australia
city: Frankston
country: Australia
facility: Frankston Hospital ( Site 0056)
state: Victoria
city: St Albans
country: Australia
facility: Western Health-Sunshine & Footscray Hospitals ( Site 0052)
state: Victoria
city: Perth
country: Australia
facility: St John of God Subiaco Hospital ( Site 0051)
state: Western Australia
city: London
country: Canada
facility: London Regional Cancer Program - London HSC ( Site 0154)
state: Ontario
city: Ottawa
country: Canada
facility: The Ottawa Hospital ( Site 0151)
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0155)
state: Ontario
city: Temuco
country: Chile
facility: Centro Investigacion Cancer James Lind ( Site 0204)
state: Araucania
city: La Serena
country: Chile
facility: IC La Serena Research ( Site 0202)
state: Coquimbo
city: Puerto Montt
country: Chile
facility: Clinica Puerto Montt ( Site 0211)
state: Los Lagos
city: Santiago
country: Chile
facility: Fundacion Arturo Lopez Perez FALP ( Site 0208)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Oncovida ( Site 0209)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Clínica Vespucio ( Site 0205)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Pontificia Universidad Catolica de Chile ( Site 0206)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Bradfordhill ( Site 0200)
state: Region M. De Santiago
city: Hefei
country: China
facility: The Second Affiliated Hospital of Anhui Medical University ( Site 1179)
state: Anhui
city: Chongqing
country: China
facility: Chongqing Cancer Hospital ( Site 1151)
state: Chongqing
city: Fuzhou
country: China
facility: Fujian Province Cancer Hospital ( Site 1178)
state: Fujian
city: Guangzhou
country: China
facility: Sun Yat-Sen University Cancer Center ( Site 1150)
state: Guangdong
city: Guangzhou
country: China
facility: Southern Medical University Nanfang Hospital ( Site 1154)
state: Guangdong
city: Guangzhou
country: China
facility: The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159)
state: Guangdong
city: Nanning
country: China
facility: Guangxi Medical University Affiliated Tumor Hospital ( Site 1158)
state: Guangxi
city: Haikou
country: China
facility: Hainan General Hospital ( Site 1177)
state: Hainan
city: Wuhan
country: China
facility: Wuhan Union Hospital Cancer Center ( Site 1162)
state: Hubei
city: Wuhan
country: China
facility: Hubei Cancer Hospital ( Site 1152)
state: Hubei
city: Changsha
country: China
facility: Xiangya Hospital Central South University ( Site 1171)
state: Hunan
city: Changsha
country: China
facility: Hunan Cancer Hospital ( Site 1174)
state: Hunan
city: Changsha
country: China
facility: The Third Xiangya Hospital of Central South University ( Site 1175)
state: Hunan
city: Changzhou
country: China
facility: Changzhou Cancer Hospital-Department of Oncology ( Site 1183)
state: Jiangsu
city: Wuxi City
country: China
facility: Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 1185)
state: Jiangsu
city: Changchun
country: China
facility: Jilin Cancer Hospital ( Site 1163)
state: Jilin
city: Jinan
country: China
facility: Jinan Central Hospital ( Site 1167)
state: Shandong
city: Shangai
country: China
facility: Fudan University Shanghai Cancer Center ( Site 1176)
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Tenth People's Hospital ( Site 1170)
state: Shanghai
city: Chengdu
country: China
facility: West China Hospital Sichuan University ( Site 1172)
state: Sichuan
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital ( Site 1161)
state: Tianjin
city: Kunming
country: China
facility: Yunnan Province Cancer Hospital-Colorectal surgery ( Site 1169)
state: Yunnan
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital ( Site 1180)
state: Zhejiang
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital-Medical Oncology ( Site 1173)
state: Zhejiang
city: Brno
country: Czechia
facility: Masarykuv onkologicky ustav ( Site 1203)
state: Brno-mesto
city: Praha
country: Czechia
facility: Fakultni nemocnice v Motole ( Site 1201)
state: Praha, Hlavni Mesto
city: Hradec Kralove
country: Czechia
facility: Fakultni nemocnice Hradec Kralove ( Site 1207)
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc ( Site 1204)
city: Praha 10
country: Czechia
facility: Fakultni nemocnice Kralovske Vinohrady ( Site 1208)
city: Praha 4
country: Czechia
facility: Fakultni Thomayerova nemocnice ( Site 1205)
city: Praha 8
country: Czechia
facility: Fakultni nemocnice Na Bulovce ( Site 1202)
city: Pessac
country: France
facility: CHU Bordeaux Haut-Leveque ( Site 0305)
state: Gironde
city: Nantes
country: France
facility: CHU Hotel Dieu Nantes ( Site 0303)
state: Pays-de-la-Loire
city: Avignon
country: France
facility: Institut du Cancer Avignon-Provence ( Site 0306)
state: Vaucluse
city: Poitiers
country: France
facility: CHU Poitiers ( Site 0304)
state: Vienne
city: Paris
country: France
facility: Hopital Europeen Georges Pompidou ( Site 0300)
city: Muenchen
country: Germany
facility: LMU Klinikum Grosshadern der Universitaet Muenchen ( Site 1253)
state: Bayern
city: Marburg
country: Germany
facility: Philipps-Universitaet Marburg. ( Site 1252)
state: Hessen
city: Wolfsburg
country: Germany
facility: Klinikum Wolfsburg ( Site 1256)
state: Niedersachsen
city: Bonn
country: Germany
facility: Johanniter Krankenhaus Bonn ( Site 1254)
state: Nordrhein-Westfalen
city: Moenchengladbach
country: Germany
facility: Kliniken Maria Hilf GmbH ( Site 1255)
state: Nordrhein-Westfalen
city: Halle (Saale)
country: Germany
facility: Universitätsklinikum Halle ( Site 1251)
state: Sachsen-Anhalt
city: Hamburg
country: Germany
facility: Katholisches Marienkrankenhaus gGmbH ( Site 1257)
city: Ashdod
country: Israel
facility: Assuta Ashdod Public ( Site 0507)
city: Haifa
country: Israel
facility: Rambam Health Care Campus-Oncology Division ( Site 0500)
city: Haifa
country: Israel
facility: Bnei Zion Medical Center ( Site 0506)
city: Jerusalem
country: Israel
facility: Hadassa Ein Karem Medical Center ( Site 0504)
city: Petah Tikva
country: Israel
facility: Rabin Medical Center ( Site 0503)
city: Ramat Gan
country: Israel
facility: Chaim Sheba Medical Center ( Site 0501)
city: Tel Aviv
country: Israel
facility: Sourasky Medical Center ( Site 0502)
city: Roma
country: Italy
facility: Policlinico Gemelli di Roma ( Site 0552)
state: Abruzzo
city: San Giovanni Rotondo
country: Italy
facility: IRCCS Casa Sollievo della Sofferenza ( Site 0554)
state: Foggia
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas - Cancer Center ( Site 0555)
state: Milano
city: Catania
country: Italy
facility: A.O. di Rilievo Nazionale e di alta Specializzazione Garibaldi ( Site 0553)
city: Milano
country: Italy
facility: ASST Grande Ospedale Metropolitano Niguarda ( Site 0550)
city: Napoli
country: Italy
facility: Universita degli Studi della Campania Luigi Vanvitelli-UOC Oncoematologia ( Site 0556)
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East ( Site 0600)
state: Chiba
city: Kita-gun
country: Japan
facility: Kagawa University Hospital ( Site 0608)
state: Kagawa
city: Osakasayama
country: Japan
facility: Kindai University Hospital ( Site 0607)
state: Osaka
city: Kitaadachi-gun
country: Japan
facility: Saitama Prefectural Cancer Center ( Site 0603)
state: Saitama
city: Sunto-gun,
country: Japan
facility: Shizuoka Cancer Center ( Site 0605)
state: Shizuoka
city: Fukuoka
country: Japan
facility: National Hospital Organization Kyushu Cancer Center ( Site 0609)
city: Tokyo
country: Japan
facility: National Cancer Center Hospital ( Site 0601)
city: Tokyo
country: Japan
facility: Japanese Foundation for Cancer Research ( Site 0602)
city: Songpagu
country: Korea, Republic of
facility: Asan Medical Center ( Site 0650)
state: Seoul
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital ( Site 0653)
city: Seoul
country: Korea, Republic of
facility: Severance Hospital ( Site 0652)
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center ( Site 0651)
city: Bangsar
country: Malaysia
facility: Pantai Hospital Kuala Lumpur ( Site 1303)
state: Kuala Lumpur
city: Petaling Jaya
country: Malaysia
facility: Beacon Hospital Sdn Bhd ( Site 1305)
state: Selangor
city: Putrajaya
country: Malaysia
facility: Institut Kanser Negara - National Cancer Institute ( Site 1302)
state: Wilayah Persekutuan Putrajaya
city: Kuala Lumpur
country: Malaysia
facility: University Malaya Medical Centre ( Site 1301)
city: Loerenskog
country: Norway
facility: Akershus universitetssykehus ( Site 1352)
state: Akershus
city: Trondheim
country: Norway
facility: St Olavs Hospital ( Site 1354)
state: Sor-Trondelag
city: Tromsoe
country: Norway
facility: Universitetssykehuset i Nord Norge. ( Site 1355)
state: Troms
city: Bergen
country: Norway
facility: Helse Bergen HF - Haukeland univeritetssykehus ( Site 1353)
state: Vestfold
city: Oslo
country: Norway
facility: Oslo Universitetssykehus HF. Ulleval ( Site 1351)
city: Ufa
country: Russian Federation
facility: Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 0871)
state: Baskortostan, Respublika
city: Kirov
country: Russian Federation
facility: SRBHI of Kirov Region Center of Oncology and medical radiology ( Site 0854)
state: Kirovskaya Oblast
city: Moscow
country: Russian Federation
facility: Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0870)
state: Moskva
city: Moscow
country: Russian Federation
facility: FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 0851)
state: Moskva
city: Saint Petersburg
country: Russian Federation
facility: City Hospital #40 ( Site 0853)
state: Sankt-Peterburg
city: Saint-Petersburg
country: Russian Federation
facility: Clinical Research Center of specialized types medical care-Oncology ( Site 0860)
state: Sankt-Peterburg
city: Tomsk
country: Russian Federation
facility: Tomsk National Research Medical Center of Russian Academy of Sciences ( Site 0872)
state: Tomskaya Oblast
city: Yaroslavl
country: Russian Federation
facility: Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0850)
state: Yaroslavskaya Oblast
city: Sankt-Peterburg
country: Russian Federation
facility: SHBI "Leningrad Regional Clinical Oncology Dispensary n.a. L.D. Roman"-Clinical Trials Department (
city: Port Elizabeth
country: South Africa
facility: Cancer Care Langenhoven Drive Oncology Centre ( Site 1504)
state: Eastern Cape
city: Sandton
country: South Africa
facility: Sandton Oncology Medical Group PTY LTD ( Site 1501)
state: Gauteng
city: Kraaifontein
country: South Africa
facility: Cape Town Oncology Trials Pty Ltd ( Site 1506)
state: Western Cape
city: Rondebosch
country: South Africa
facility: Cancercare Rondebosch Oncology ( Site 1509)
state: Western Cape
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d Hebron ( Site 0900)
city: Barcelona
country: Spain
facility: Hospital Sant Pau i la Santa Creu ( Site 0905)
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos ( Site 0902)
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre ( Site 0901)
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena ( Site 0906)
city: Kaohsiung
country: Taiwan
facility: Chang Gung Medical Foundation - Kaohsiung ( Site 0956)
state: Changhua
city: Taichung
country: Taiwan
facility: China Medical University Hospital ( Site 0953)
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital ( Site 0955)
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital ( Site 0950)
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital ( Site 0951)
city: Taoyuan
country: Taiwan
facility: Chang Gung Medical Foundation. Linkou ( Site 0952)
city: Adana
country: Turkey
facility: Baskent Universitesi Dr. Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1007)
city: Adana
country: Turkey
facility: Acibadem Adana Hastanesi ( Site 1008)
city: Ankara
country: Turkey
facility: Gulhane Egitim ve Arastirma Hastanesi ( Site 1009)
city: Ankara
country: Turkey
facility: Hacettepe Universitesi Tip Fakultesi ( Site 1003)
city: Ankara
country: Turkey
facility: Ankara Sehir Hastanesi ( Site 1005)
city: Antalya
country: Turkey
facility: Antalya Egitim ve Arastirma Hastanesi ( Site 1010)
city: Istanbul
country: Turkey
facility: Goztepe Prof.Dr. Suleyman Yalcin Sehir Hastanesi ( Site 1002)
city: Izmir
country: Turkey
facility: Ege Universitesi Tip Fakultesi Hastanesi ( Site 1006)
city: Dnipro
country: Ukraine
facility: Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 1657)
state: Dnipropetrovska Oblast
city: Ivano-Frankivsk
country: Ukraine
facility: MI Precarpathian Clinical Oncology Center ( Site 1654)
state: Ivano-Frankivska Oblast
city: Kropyvnytskyi
country: Ukraine
facility: Ukrainian Center of Tomotherapy ( Site 1658)
state: Kirovohradska Oblast
city: Odesa
country: Ukraine
facility: Odessa Regional Clinical Hospital ( Site 1664)
state: Odeska Oblast
city: London
country: United Kingdom
facility: University College London Hospitals NHS Foundation Trust ( Site 1056)
state: Camden
city: London
country: United Kingdom
facility: Royal Marsden NHS Foundation Trust ( Site 1064)
state: London, City Of
city: London
country: United Kingdom
facility: Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 1052)
state: London, City Of
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS Trust ( Site 1063)
state: London, City Of
city: Coventry
country: United Kingdom
facility: University Hospital Coventry & Warwickshire ( Site 1062)
state: Warwickshire
city: Cardiff
country: United Kingdom
facility: Velindre Cancer Centre ( Site 1058)
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hospitals NHS Trust ( Site 1050)
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: